Novel therapeutic strategies to target RCAS1, which induces apoptosis via ectodomain shedding

Histology and Histopathology

Volumn 26, Issue 11, 2011, Pages 1475-1486

  Sonoda, Kenzo ^a  

^a KYUSHU UNIVERSITY   (Japan)

Author keywords

Apoptosis; Biomarker; Ectodomain shedding; RCAS1; Targeting therapy

Indexed keywords

EBAG9 PROTEIN, HUMAN; TUMOR ANTIGEN; TUMOR MARKER;

ANIMAL; APOPTOSIS; HUMAN; METABOLISM; NEOPLASM; PHYSIOLOGY; REVIEW;

ANIMALS; ANTIGENS, NEOPLASM; APOPTOSIS; HUMANS; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 80053177112     PISSN: 02133911     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Akashi T., Oimomi H., Nishiyama K., Nakashima M., Arita Y., Sumii T., Kimura T., Ito T., Nawata H. and Watanabe T. (2003). Expression and diagnostic evaluation of the human tumor-associated antigen RCAS1 in pancreatic cancer. Pancreas 26, 49-55.
2. Allison M. (2008). Is personalized medicine finally arriving? Nat. Biotechnol. 26, 509-517.
3. Aoe K., Hiraki A., Maeda T., Murakami T., Yamazaki K., Sugi K. and Takeyama H. (2004). Soluble receptor-binding cancer antigen expressed on SiSo cells in pleural fluid: a potential diagnostic marker for malignant pleural effusion. Chest 126, 1195-1197.
4. Aoe K., Hiraki A., Yamazaki K., Nakamura Y., Murakami T., Maeda T., Nishimura M., Sugi K. and Ueoka H. (2006). Elevated pleural fluid RCAS1 is a diagnostic marker and outcome predictor in lung cancer patients. Int. J. Oncol. 29, 65-72.
5. Aoki T., Inoue S., Imamura H., Fukushima J., Takahashi S., Urano T., Hasegawa K., Ogushi T., Ouchi Y. and Makuuchi M. (2003). EBAG9/RCAS1 expression in hepatocellular carcinoma: correlation with tumour dedifferentiation and proliferation. Eur. J. Cancer 39, 1552-1561.
6. Bhowmick N.A. and Moses H.L. (2005). Tumor-stromal interactions. Curr. Opin. Genet. Dev. 15, 97-101.
7. Bolos V., Gasent J.M., Lopez-Tarruella S. and Grande E. (2010). The dual kinase complex FAK-Src as a promising therapeutic target in cancer. OncoTargets Ther. 3, 83-97.
8. Brinkerhoff C.E., Rutter J.L. and Benbow U. (2000). Interstitial collagenases as markers of tumor progression. Clin. Cancer Res. 6, 4823-4830.
9. Byun Y., Chen F., Chang R., Trivedi M., Green K.J. and Cryns V.L. (2001). Caspase cleavage of vimentin disrupts intermediate filaments and promotes apoptosis. Cell Death Differ. 8, 443-450.
10. Chien A.J., IIIi J.A., Ko A.H., Korn W.M., Fong L., Chen L.M., Kashani-Sabet M., Ryan C.J., Rosenberg J.E., Dubey S., Small E.J., Jahan T.M., Hylton N.M., Yeh B.M., Huang Y., Koch K.M. and Moasser M.M. (2009). A phase I study of a 2-day lapatinib chemosensitization pulse preceding nanoparticle albumin-bound paclitaxel for advanced solid malignancies. Clin. Cancer Res. 15, 5569-5575.
11. Coban S., Ozkan H., Koklu S., Yuksel O., Kockar M.C., Akar T. and Ormeci N. (2006). The utility of serum receptor-binding cancer antigen expressed on SiSo cells in gastrointestinal tract cancers. Can. J. Gastroenterol. 20, 593-596.
12. Davis G.E. and Senger D.R. (2005). Endothelial extracellular matrix. Biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ. Res. 97, 1093-1107.
13. Dutsch-Wicherek M. and Wicherek L. (2008). The association of RCAS1 serum concentration with the reversibility or irreversibility of the process of immune cytotoxic activity restriction during normal menstrual cycle, cancer relapse, and surgical treatment for various types of squamous cell carcinomas and adenocarcinomas. Am. J. Reprod. Immunol. 59, 266-275.
14. Dutsch-Wicherek M., Tomaszewska R., Lazar A., Wicherek L. and Skladzien J. (2009). The association between RCAS1 expression in laryngeal and pharyngeal cancer and its healthy stroma with cancer relapse. BMC Cancer 9, 35-44.
15. Eckes B., Dogic D., Colucci-Guyon E., Wang N., Maniotis A., Ingber D., Merckling A., Langa F., Aumailley M., Delouvee A., Koteliansky V., Babinet C. and Krieg T. (1998). Impaired mechanical stability, migration and contractile capacity in vimentin-deficient fibroblasts. J. Cell Sci. 111, 1897-1907.
16. Enjoji M., Nakashima M., Nishi H., Choi I., Oimomi H., Sugimoto R., Kotoh K., Taguchi K., Nakamuta M., Nawata H. and Watanabe T. (2002). The tumor-associated antigen, RCAS1, can be expressed in immune-mediated diseases as well as in carcinomas of biliary tract. J. Hepatol. 36, 786-792.
17. Enjoji M., Noguchi K., Watanabe H., Yoshida Y., Kotoh K., Nakashima M., Watanabe T., Nakamuta M. and Nawata H. (2003). A novel tumour marker RCAS1 in a case of extramammary Paget's disease. Clin. Exp. Dermatol. 28, 211-213.
18. Enjoji M., Yamaguchi K., Nakashima M., Ohta S., Kotoh K., Fukushima M., Kuniyoshi M., Tanaka M., Nakamuta M., Watanabe T. and Nawata H. (2004a). Serum levels of soluble molecules associated with evasion of immune surveillance: a study in biliary disease. Liver Int. 24, 330-334.
19. Enjoji M., Yamaguchi K., Nakamuta M., Nakashima M., Kotoh K., Tanaka M., Nawata H. and Watanabe T. (2004b). Movement of a novel serum tumour marker, RCAS1, in patients with biliary diseases. Dig. Liver Dis. 36, 622-627.
20. Elbashir S.M., Lendeckel W. and Tuschl T. (2001). RNA interference is mediated by 21-and 22-nucleotide RNAs. Genes Dev. 15, 188-200.
21. Fan H. and Derynck R. (1999). Ectodomain shedding of TGF-a and other transmembrane proteins is induced by receptor tyrosine kinase activation and MAP kinase signaling cascades. EMBO J. 18, 6962-6972.
22. Finn R.S. (2010). Development of molecularly targeted therapies in hepatocellular carcinoma: where do we go now? Clin. Cancer Res. 16, 390-397.
23. Fukuda K., Tsujitani S., Maeta Y., Yamaguchi K., Ikeguchi M. and Kaibara N. (2002). The expression of RCAS1 and tumor infiltrating lymphocytes in patients with T3 gastric carcinoma. Gastric Cancer 5, 220-227.
24. Fukuda M., Tanaka A., Hamao A., Suzuki S., Kusama K. and Sakashita H. (2004). Expression of RCAS1 and its function in human squamous cell carcinoma of the oral cavity. Oncol. Rep. 12, 259-267.
25. Giaginis C., Giagini A. and Theocharis S. (2009a). Receptor-binding cancer antigen expressed on SiSo cells (RCAS1): a novel biomarker in the diagnosis and prognosis of human neoplasia. Histol. Histopathol. 24, 761-776.
26. Giaginis C., Margeli A., Kouraklis G., Zira A., Tsourouflis G. and Theocharis S. (2009b). Diagnostic and prognostic utility of serum receptor-binding cancer antigen expressed on SiSo cells (RCAS1) levels in colon cancer patients. Int. J. Biol. Markers 24, 70-76.
27. Ginsburg G.S. and McCarthy J.J. (2001). Personalized medicine: revolutionizing drug discovery and patient care. Trends Biotechnol. 19, 491-496.
28. Hainsworth J.D., Sosman J.A., Spigel D.R., Edwards D.L., Baughman C. and Greco A. (2005). Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib. J. Clin. Oncol. 23, 7889-7896.
29. Han Y., Qin W. and Huang G. (2007). Knockdown of RCAS1 expression by RNA interference recovers T cell growth and proliferation. Cancer Lett. 257, 182-190.
30. Hiraoka K., Hida Y., Miyamoto M., Oshikiri T., Suzuoki M., Nakakubo Y., Shinohara T., Itoh T., Shichinohe T., Kondo S., Kasahara N. and Katoh H. (2002). High expression of tumor-associated antigen RCAS1 in pancreatic ductal adenocarcinoma is an unfavorable prognostic marker. Int. J. Cancer 99, 418-423.
31. Hong X.J., Shen F.P. and Wang Q.Q. (2006). Construction of recombinant GST-RCAS1 fusion gene and its expression in E. coli. Zhejiang Da Xue Xue Bao Yi Xue Ban 35, 377-383.
32. Hotte S.J., Hirte H.W., Chen E.X., Siu L.L., Le L.H., Corey A., Iacobucci A., MacLean M., Lo L., Fox N.L. and Oza A.M. (2008). A Phase 1 study of mapatumumab (fully human monoclonal antibody to TRAILR1) in patients with advanced solid malignancies. Clin. Cancer Res. 14, 3450-3455.
33. Hynes N.E. and Schlange T. (2006). Targeting ADAMS and ERBBs in lung cancer. Cancer Cell 10, 7-11.
34. Ikeda K., Sato M., Tsutsumi O., Tsuchiya F., Tsuneizumi M., Emi M., Imoto I., Inazawa J., Muramatsu M. and Inoue S. (2000). Promoter analysis and chromosomal mapping of human EBAG9 gene. Biochem. Biophys. Res. Commun. 273, 654-660.
35. Ito Y., Yoshida H., Nakano K., Kobayashi K., Yokozawa T., Hirai K., Matsuzuka F., Matsuura N., Kuma K. and Miyauchi A. (2003). Overexpression of human tumor-associated antigen, RCAS1, is significantly linked to dedifferentiation of thyroid carcinoma. Oncology 64, 83-89.
36. Iwasaki T., Nakashima M., Watanabe T., Yamamoto S., Inoue Y., Yamanaka H., Matsumura A., Iuchi K., Mori T. and Okada M. (2000). Expression and prognostic significance in lung cancer of human tumor-associated antigen RCAS1. Int. J. Cancer 89, 488-493.
37. Izumi M., Nakanishi Y., Yoshino I., Nakashima M., Watanabe T. and Hara N. (2001). Expression of tumor-associated antigen RCAS1 correlates significantly with poor prognosis in nonsmall cell lung carcinoma. Cancer 92, 446-451.
38. Izumi Y., Hirata M., Hasuwa H., Iwamoto R., Umata T., Miyado K., Tamai Y., Kurisaki T., Sehara-Fujisawa A., Ohno S. and Mekada E. (1998). A metalloprotease-disintegrin, MDC9/meltrin-Á/ADAM9 and PKC‰ are involved in TPA-induced ectodomain shedding of membrane-anchored heparin-binding EGF-like growth factor: EMBO J. 17, 7260-7272.
39. Jain K.K. (2002). Personalized medicine. Curr. Opin. Mol. Ther. 4, 548-558.
40. Jain R.K., Duda D.G., Willett C.G., Sahani D.V., Zhu A.X., Loeffler J.S., Batchelor T.T. and Sorensen A.G. (2009). Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 6, 327-338.
41. Karlan B.Y., Baldwin R.L., Cirisano F.D., Mamula P.W., Jones J. and Lagasse L.D. (2002). Secreted ovarian stromal substance inhibits ovarian epithelial cell proliferation. Gynecol. Oncol. 59, 67-74.
42. Kataoka H. (2009). EGFR ligands and their signaling scissors, ADAMs, as new molecular targets for anticancer treatments. J. Dermatol. Sci. 56, 148-153.
43. Kato H., Nakajima M., Masuda N., Faried A., Sohda M., Fukai Y., Miyazaki T., Fukuchi M., Tsukada K. and Kuwano H. (2005). Expression of RCAS1 in esophageal squamous cell carcinoma is associated with a poor prognosis. J. Surg. Oncol. 90, 89-94.
44. Kim J.B., Stein R. and O'Hare M.J. (2005). Tumor-stromal interactions in breast cancer: the role of stroma in tumorigenesis. Tumor Biol. 26, 173-185.
45. Kokkinos M.I., Wafai R., Wong M.K., Newgreen D.F., Thompson E.W. and Waltham M. (2007). Vimentin and epithelial-mesenchymal transition in human breast cancer - observations in vitro and in vivo. Cells Tissues Organs 185, 191-203.
46. Koopman M., Venderbosch S., Nagtegaal I.D., van Krieken J.H. and Punt C.J. (2009). A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? Eur. J. Cancer 45, 1935-1949.
47. Kubokawa M., Nakashima M., Yao T., Ito K., Harada N., Nawata H. and Watanabe T. (2001). Aberrant intracellular localization of RCAS1 is associated with tumor progression of gastric cancer. Int. J Oncol. 19, 695-700.
48. Kulasingam V., Pavlou M.P. and Diamandis E.P. (2010). Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat. Rev. Cancer 10, 371-378.
49. Leelawat K., Watanabe T., Nakajima M., Tujinda S., Suthipintawong C. and Leardkamolkarn V. (2003). Upregulation of tumour associated antigen RCAS1 is implicated in high stages of colorectal cancer. J. Clin. Pathol. 56, 764-768.
50. Liby T.A., Spyropoulos P., Lindner H.B., Eldridge J., Beeson C., Hsu T. and Muise-Helmericks R.C. (2011). Akt3 controls VEGF secretion and angiogenesis in ovarian cancer cells. Int. J. Cancer (in press).
51. Massague J. and Pandiella A. (1993). Membrane-anchored growth factors. Annu. Rev. Biochem. 62, 515-541.
52. McNeel D.G., Eickhoff J., Lee F.T., King D.M., Alberti D., Thomas J.P., Friedl A., Kolesar J., Marnocha R., Volkman J., Zhang J., Hammershaimb L., Zwiebel J.A. and Wilding G. (2005). Phase I trial of a monoclonal antibody specific for avß3 integrin (MEDI-522) in patients with advanced malignancies, including an assessment of effect on tumor perfusion. Clin. Cancer Res. 11, 7851-7860.
53. Merchant N.B., Voskresensky I., Rogers C.M., LaFleur B., Dempsey P.J., Graves-Deal R., Revetta F., Coe Foutch A., Rothenberg M.L., Washington M.K. and Coffey R.J. (2008). TACE/ADAM-17: a component of the epidermal growth factor receptor axis and a promising therapeutic target in colorectal cancer. Clin. Cancer Res. 14, 1182-1191.
54. Mullenders J. and Bernards R. (2009). Loss-of-function genetic screens as a tool to improve the diagnosis and treatment of cancer. Oncogene 28, 4409-4420.
55. Murukesh N., Dive C. and Jayson G.C. (2010). Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br. J. Cancer 102, 8-18.
56. Nakabayashi H., Nakashima M., Hara M., Toyonaga S., Yamada S.M., Park K.C. and Shimizu K. (2007). Clinico-pathological significance of RCAS1 expression in gliomas: a potential mechanism of tumor immune escape. Cancer Lett. 246, 182-189.
57. Nakakubo Y., Hida Y., Miyamoto M., Hashida H., Oshikiri T., Kato K., Suzuoki M., Hiraoka K., Ito T., Morikawa T., Okushiba S., Kondo S. and Katoh H. (2002). The prognostic significance of RCAS1 expression in squamous cell carcinoma of the oesophagus. Cancer Lett. 177, 101-105.
58. Nakamura Y., Yamazaki K., Oizumi S., Nakashima M., Watanabe T., Dosaka-Akita H. and Nishimura M. (2004). Expression of RCAS1 in human gastric carcinoma: a potential mechanism of immune escape. Cancer Sci. 95, 260-265.
59. Nakashima M., Sonoda K. and Watanabe T. (1999). Inhibition of cell growth and induction of apoptotic cell death by the human tumorassociated antigen RCAS1. Nat. Med. 5, 938-942.
60. Natoli G., Costanzo A., Guido F., Moretti F. and Lavrero M. (1998). Apoptotic, non-apoptotic, and anti-apoptotic pathways of tumor necrosis factor signaling. Biochem. Pharmacol. 56, 915-920.
61. Nieminen M., Henttinen T., Merinen M., Narttila-Ichihara F., Eriksson J.E. and Jalkanen S. (2006). Vimentin function in lymphocyte adhesion and transcellular migration. Nat. Cell Biol. 8, 156-162.
62. Nilsson E.E. and Skinner M.K. (2002). Role of transforming growth factor beta in ovarian surface epithelium biology and ovarian cancer. Reprod. Biomed. Online 5, 254-258.
63. Nishinakagawa T., Fujii S., Nozaki T., Maeda T., Machida K., Enjoji M. and Nakashima M. (2010). Analysis of cell cycle arrest and apoptosis induced by RCAS1. Int. J. Mol. Med. 25,717-722.
64. Ogushi T., Takahashi S., Takeuchi T., Urano T., Horie-Inoue K., Kumagai J., Kitamura T., Ouchi Y., Muramatsu M. and Inoue S. (2005). Estrogen receptor-binding fragment-associated antigen 9 is a tumor-promoting and prognostic factor for renal cell carcinoma. Cancer Res. 65, 3700-3706.
65. Okada K., Nakashima M., Komuta K., Hashimoto S., Okudaira S., Baba N., Hishikawa Y., Koji T., Kanematsu T. and Watanabe T. (2003). Expression of tumor-associated membrane antigen, RCAS1, in human colorectal carcinomas and possible role in apoptosis of tumor-infiltrating lymphocytes. Mod. Pathol. 16, 679-685.
66. Okamura Y., Ma Z., Khatlani T.S., Okuda M., Une S., Nakaichi M. and Taura Y. (2003). Molecular cloning of canine RCAS1 cDNA. J. Vet. Med. Sci. 65, 913-915.
67. Okamura Y., Haraguchi T., Morimoto M., Okuda M., Une S., Nakaichi M. and Taura Y. (2004). Expression of a tumor-associated antigen, RCAS1, in canine mammary tumors. J. Vet. Med. Sci. 66, 651-658.
68. Oshikiri T., Hida Y., Miyamoto M., Hashida H., Katoh K., Suzuoki M., Nakakubo Y., Hiraoka K., Shinohara T., Itoh T., Kondo S. and Katoh H. (2001). RCAS1 as a tumour progression marker: an independent negative prognostic factor in gallbladder cancer. Br. J. Cancer 85, 1922-1927.
69. Ozkan H., Akar T., Koklu S. and Coban S. (2006). Significance of serum receptor-binding cancer antigen (RCAS1) in pancreatic cancer and benign pancreatobiliary diseases. Pancreatology 6, 268-272.
70. Ozpolat B., Sood A.K. and Lopez-Berestein G. (2010). Nanomedicine based approaches for the delivery of siRNA in cancer. J. Intern. Med. 267, 44-53.
71. Phan J.H., Moffitt R.A., Stokes T.H., Liu J., Young A.N., Nie S. and Wang M.D. (2009). Convergence of biomarkers, bioinformatics and nanotechnology for individualized cancer treatment. Trends Biotechnol. 27, 350-358.
72. Przybylo J.A. and Radisky D.C. (2007). Matrix metalloproteinaseinduced epithelial-mesenchymal transition: tumor progression at Snail's pace. Int. J. Biochem. Cell Biol. 39, 1082-1088.
73. Qi H., Rand M.D., Wu X., Sestan N., Wang W., Rakic P., Xu T. and Artavanis-Tsakonas S. (1999). Processing of the Notch ligand delta by the metalloprotease Kuzbanian. Science 238, 91-94.
74. Razvi K., Sonoda K., Lee Y.S., Tham K.F., Lim F.K. and Yong E.L. (1999). A preliminary study of the immunohistochemistry detection of a novel tumour marker, 22-1-1 antigen, in gynaecological cancer specimens. Ann. Acad. Med. Singapore 28, 392-394.
75. Rousseau J., Tetu B., Caron D., Malenfant P., Cattaruzzi P., Audette M., Doillon C., Tremblay J.P. and Guerette B. (2002). RCAS1 is associated with ductal breast cancer progression. Biochem. Biophys. Res. Commun. 293, 1544-1549.
76. Sandgren E.P., Luetteke N.C., Palmiter R.E., Brinster R.L. and Lee D.C. (1990). Overexpression of TGF-· in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia and carcinoma of the breast. Cell 61, 1121-1135.
77. Schwartz J.D., Rowinsky E.K., Youssoufian H., Pytowski B. and Wu Y. (2010). Vascular endothelial growth factor receptor-1 in human cancer. Cancer 116, 1027-1032.
78. Schweitzer R., Shaharabany M., Segar R. and Shilo B.Z. (1995). Secreted Spitz triggers the DER signaling pathway and is a limiting component in embryonic ventral ectoderm determination. Genes Dev. 9, 1518-1529.
79. Siena S., Sartore-Bianchi A., Nicolantonio F.D., Balfour J. and Bardelli A. (2009). Biomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer. J. Natl. Cancer Inst. 101, 1308-1324.
80. Skyldberg B., Salo S., Eriksson E., Aspenblad U., Moberger B., Tryggvason K. and Auer G. (1999). Laminin-5 as a marker of invasiveness in cervical lesions. J. Natl. Cancer Inst. 91, 1882-1887.
81. Sonoda K., Nakashima M., Kaku T., Kamura T., Nakano H. and Watanabe T. (1996). A novel tumor-associated antigen expressed in human uterine and ovarian carcinomas. Cancer 77, 1501-1509.
82. Sonoda K., Kaku T., Kamura T., Nakashima M., Watanabe T. and Nakano H. (1998). Tumor-associated antigen 22-1-1 expression in the uterine cervical squamous neoplasia. Clin. Cancer Res. 4, 1517-1520.
83. Sonoda K., Kaku T., Hirakawa T., Kobayashi H., Amada S., Sakai K., Nakashima M., Watanabe T. and Nakano H. (2000). The clinical significance of tumor-associated antigen RCAS1 expression in the normal, hyperplastic, and malignant uterine endometrium. Gynecol. Oncol. 79 424-429.
84. Sonoda K., Miyamoto S., Hirakawa T., Kaku T., Nakashima M., Watanabe T., Akazawa K., Fujita T. and Nakano H. (2003). Association between RCAS1 expression and clinical outcome in uterine endometrial cancer. Br. J. Cancer 89, 546-551.
85. Sonoda K., Miyamoto S., Hirakawa T., Yagi H., Yotsumoto F., Nakashima M., Watanabe T. and Nakano H. (2005a). Invasive potency related to RCAS1 expression in uterine cervical cancer. Gynecol. Oncol. 99, 189-198.
86. Sonoda K., Miyamoto S., Hirakawa T., Yagi H., Yotsumoto F., Nakashima M., Watanabe T. and Nakano H. (2005b). Association between RCAS1 expression and microenvironmental immune cell death in uterine cervical cancer. Gynecol. Oncol. 97, 772-779.
87. Sonoda K., Miyamoto S., Hirakawa T., Yagi H., Yotsumoto F., Nakashima M., Watanabe T. and Nakano H. (2006). Clinical significance of RCAS1 as a biomarker of uterine cancer. Gynecol. Oncol. 103, 924-931.
88. Sonoda K., Miyamoto S., Yotsumoto F., Yagi H., Nakashima M., Watanabe T. and Nakano H. (2007a). Clinical significance of RCAS1 as a biomarker of ovarian cancer. Oncol. Rep. 17, 623-628.
89. Sonoda K., Miyamoto S., Yamazaki A., Kobayashi H., Nakashima M., Mekada E. and Wake N. (2007b). Biologic significance of receptorbinding cancer antigen expressed on SiSo cells (RCAS1) as a pivotal regulator of tumor growth through angiogenesis in human uterine cancer. Cancer 110, 1979-1990.
90. Sonoda K., Miyamoto S., Nakashima M. and Wake N. (2008). The biological role of unique molecule RCAS1: a bioactive marker that induces connective tissue remodeling and lymphocyte apoptosis. Front. Biosci. 13, 1106-1116.
91. Sonoda K., Miyamoto S., Kobayashi H., Ogawa S., Okugawa K., Taniguchi S. and Wake N. (2009). The level of RCAS1 expression is inversely correlated with the number of vimentin-positive stromal cells in epithelial ovarian cancer. Int. J. Gynecol. Cancer 19, 838-843.
92. Sonoda K., Miyamoto S., Nakashima M. and Wake N. (2010). Receptorbinding cancer antigen expressed on SiSo cells induces apoptosis via ectodomain shedding. Exp. Cell Res. 316, 1795-1803.
93. Suzuki T., Inoue S., Kawabata W., Akahira J., Moriya T., Tsuchiya F., Ogawa S., Muramatsu M. and Sasano H. (2001). EBAG9/RCAS1 in human breast carcinoma: a possible factor in endocrine-immune interactions. Br. J. Cancer 85, 1731-1737.
94. Toyoshima T., Nakamura S., Kumamaru W., Kawamura E., Ishibashi H., Hayashida J.N., Moriyama M., Ohyama Y., Sasaki M. and Shirasuna K. (2006). Expression of tumor-associated antigen RCAS1 and its possible involvement in immune evasion in oral squamous cell carcinoma. J. Oral Pathol. Med. 35, 361-368.
95. Tsuchiya F., Ikeda K., Tsutsumi O., Hiroi H., Momoeda M., Taketani Y., Muramatsu M. and Inoue S. (2001). Molecular cloning and characterization of mouse EBAG9, homolog of a human cancer associated surface antigen: expression and regulation by estrogen. Biochem. Biophys. Res. Commun. 284, 2-10.
96. Tsujitani S., Saito H., Oka S., Sakamoto T., Kanaji S., Tatebe S. and Ikeguchi M. (2007). Prognostic significance of RCAS1 expression in relation to the infiltration of dendritic cells and lymphocytes in patients with esophageal carcinoma. Dig. Dis. Sci. 52, 549-554.
97. Vokes E.E. and Choy H. (2003). Targeted therapies for stage III nonsmall cell lung cancer: integration in the combined modality setting. Lung Cancer 41, S115-S121.
98. Wajant H., Pfizenmaier K. and Scheurich P. (2003). Non-apoptotic Fas signaling. Cytokine Growth Factor Rev. 14, 53-66.
99. Watanabe H., Enjoji M., Nakashima M., Noguchi K., Kinukawa N., Sugimoto R., Kotoh K., Nakamuta M., Nawata H. and Watanabe T. (2003). Clinical significance of serum RCAS1 levels detected by monoclonal antibody 22-1-1 in patients with cholangiocellular carcinoma. J. Hepatol. 39, 559-563.
100. Weiner L.M., Surana R. and Wang S. (2010). Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat. Rev. Immunol. 10, 317-327.
101. Witters L., Scherle P., Friedman S., Friedman J., Caulder E., Newton R. and Lipton A. (2008). Synergistic inhibition with a dual epidermal growth factor receptor/HER-2/neu tyrosine kinase inhibitor and a disintegrin and metalloprotease inhibitor. Cancer Res. 68, 7083-7089.
102. Yamaguchi K., Enjoji M., Nakashima M., Nakamuta M., Watanabe T. and Tanaka M. (2005). Novel serum tumor marker, RCAS1, in pancreatic diseases. World J. Gastroenterol. 11, 5199-5202.
103. Yoshida Y., Koga K., Watanabe T., Koga M., Takahashi A., Nakayama J. and Yamamoto O. (2008). Potential utility of the tumour marker RCAS1 for monitoring patients with invasive extramammary Paget's disease. Acta. Derm. Venereol. 88, 296-297.
104. Yotsumoto F., Sanui A., Fukami T., Shirota K., Horiuchi S., Tsujioka H., Yoshizato T., Kuroki M. and Miyamoto S. (2009). Efficacy of ligandbased targeting for the EGF system in cancer. Anticancer Res. 29, 4879-4886.